18 past transactions

Autotelic Bio

Series B in 2022
Autotelic Bio is a bio technology company that researches and develops anti-cancer drugs.

BnH Research

Series B in 2022
BnH Research develops therapeutics for patients suffering from chronic conditions.

BIORCHESTRA

Series C in 2022
BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

HMC Networks

Series B in 2021
Hmcnetworks leads service innovation, resolving the imbalance of information in the medical industry by using big data.

Pharos iBio Co.

Series C in 2021
Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases.

Connext

Series A in 2021
Connext is developing biological therapeutics in the field of immuno-oncology and regenerative medicine.

Rznomics

Series B in 2021
This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.

Biobab AiBIO

Series A in 2021
Biobab AiBIO is a biotechnology company that develops drugs utilize artificial intelligence.

PeLeMed

Series A in 2020
PeLeMed is a drug development company working on the discovery of anti-cancer drugs. The company's innovative therapeutic candidates through type 1 kinase inhibitor development platform.

BioSquare

Series A in 2020
BioSquare is a biotechnology company that provides point of care testing devices.

CORELINESOFT

Series B in 2020
CORELINESOFT develops medical software products.

BnH Research

Series A in 2020
BnH Research develops therapeutics for patients suffering from chronic conditions.

HMC Networks

Series A in 2020
Hmcnetworks leads service innovation, resolving the imbalance of information in the medical industry by using big data.

Hutom

Series A in 2018
Hutom offers a surgical service platform that includes an interactive report that is used to manage patient complications and has a positive impact on the surgeon's surgical methods. Its platform begins with an intuitive, analytical diagnosis of the patient's specificity, followed by a simulated examination of the surgery via surgical video processing, recognition, analysis, and prediction.

Hutom

Series A in 2018
Hutom offers a surgical service platform that includes an interactive report that is used to manage patient complications and has a positive impact on the surgeon's surgical methods. Its platform begins with an intuitive, analytical diagnosis of the patient's specificity, followed by a simulated examination of the surgery via surgical video processing, recognition, analysis, and prediction.

Lemon Healthcare

Series A in 2018
Lemon Healthcare is a one-stop mobile solution that offers smart medical services. Lemon Healthcare employs ICT-based technology to solve challenges in medical institutions, such as when patients make reservations, manage health data, and make payments. Furthermore, the company creates platforms such as mobile smart hospitals by connecting hospitals, pharmacies, and insurance companies.

Value and Trust

Series A in 2017
Value and Trust is a manufacturer of medical devices that can effectively treat different types of scoliosis.

Medizen Humancare

Series A in 2014
Genetic disease risk analysis service through M-CHECK (My Genome Check), a system for analyzing individual genes and biomarkers of Korean and various races developed by the head office, will be a guide to disease prevention and health life extension. is.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.